Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Darzalex
CAS 945721-28-8
On November 16, 2015, the us FDA approved the release of Daratumumab, a new monoclonal antibody drug made by Janssen and marketed under the trade name Darzalex. Clinical use of multiple myeloma after treatment with protease inhibitors and immunosuppressive agents. The bioengineered drug is an anti-cd38 monoclonal antibody that targets a transmembrane extracellular enzyme CD38 molecule highly expressed on the surface of multiple myeloma cells and can induce rapid death of tumor cells through a variety of mechanisms. Because healthy cells and all myeloma cells express CD38, adequate evaluation of drug toxicity and therapeutic efficacy is required.
We can customize according to customer's requirement
if you have any question pls mail us or call us
